Skip to main content
. 2022 Jun 16;16:1827–1845. doi: 10.2147/DDDT.S281631

Figure 3.

Figure 3

Metabolism of givosiran.

Note: Li J, Liu J, Zhang X, et al. Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion of givosiran, the first approved N-Acetylgalactosamine-conjugated RNA interference therapeutic. Drug Metab Dispos. 2021;49(7):572–580.51